Hong Kong says initial study of BioNTech vaccines shows ‘obvious systemic factors’

HONG KONG (Reuters) – The Hong Kong government said an initial study by BioNTech and Fosun Industrial of the coronavirus vaccine did not reveal “obvious systemic factors” at the time of packaging after canceling the vaccine in the city and neighboring Macau this week.

A sign can be seen outside a vaccination center after Hong Kong banned the coronavirus infection vaccine (COVID-19) from a single batch of Pfizer / BioNTech photos due to packaging defects, in Hong Kong, China March 24, 2021. REUTERS / Tyrone Siu

Authorities on Wednesday stopped the use of the COVID-19 vaccine developed by BioNTech citing deficient packaging, triggering upheaval in security centers across the city.

The ban was lifted because an Asian financial hub has opposed slow vaccination uptake due to declining confidence in Sinovac vaccination in China and fears of adverse reactions.

In a statement released late on Saturday, the city government said the results of the study did not claim the situation was “caused by environmental conditions during the lengthy transportation process. ”

It was not related to the cold and supply chain management of the vaccine and randomized trials of whole filters delivered to Hong Kong found no case of leakage, he said.

Both Fosun and BioNTech believed that the vaccines posed no safety risks and that those who received them did not have to “worry”, the government said.

The other part of the study will focus on “ascertaining the integrity of the sexual properties in the relevant captures of the vaccine, and that the glasses are safe for use. ”

The government said it was following up with Fosun and BioNTech to complete the study within a week to allow a resumption of distribution of the vaccines to the public.

The city began vaccinating residents with doses from Sinovac in February and began offering the one developed by BioNTech in March.

The BioNTech vaccine is distributed in Hong Kong and Macau through a partnership with Fosun Pharma in China, while BioNTech is partnering with Pfizer in larger markets outside China.

Reporting by Farah Master; Edited by Daniel Wallis